AlloVir (ALVR)
(Delayed Data from NSDQ)
$0.79 USD
-0.03 (-4.01%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $0.78 -0.01 (-0.70%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth F Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ALVR 0.79 -0.03(-4.01%)
Will ALVR be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ALVR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALVR
Are Medical Stocks Lagging AlloVir (ALVR) This Year?
Down -72.39% in 4 Weeks, Here's Why You Should You Buy the Dip in AlloVir, Inc. (ALVR)
ALVR: What are Zacks experts saying now?
Zacks Private Portfolio Services
5 Stocks With Rising P/E to Bet on for Solid Gains
5 Top-Ranked Stocks With Rising P/E Worth Investing In
Eliem (ELYM) to Explore Strategic Options, Stock Rises 6%
Other News for ALVR
Maintaining Hold on AlloVir Amid Financial Performance and Strategic Uncertainty
Morgan Stanley Sticks to Its Sell Rating for AlloVir (ALVR)
ALVR Stock Earnings: AlloVir Beats EPS for Q2 2024